DI COSTANZO, FRANCESCO
 Distribuzione geografica
Continente #
NA - Nord America 2.441
EU - Europa 1.833
AS - Asia 1.025
SA - Sud America 92
AF - Africa 19
OC - Oceania 7
Totale 5.417
Nazione #
US - Stati Uniti d'America 2.408
RU - Federazione Russa 605
PL - Polonia 424
IT - Italia 320
SG - Singapore 310
CN - Cina 242
HK - Hong Kong 145
IE - Irlanda 120
VN - Vietnam 114
SE - Svezia 105
BR - Brasile 72
FI - Finlandia 70
KR - Corea 68
FR - Francia 46
DE - Germania 42
IN - India 39
JO - Giordania 34
GB - Regno Unito 31
CA - Canada 20
ID - Indonesia 18
JP - Giappone 15
BD - Bangladesh 13
ES - Italia 12
UA - Ucraina 12
AT - Austria 11
IQ - Iraq 8
AR - Argentina 7
AU - Australia 7
BE - Belgio 7
CH - Svizzera 7
MX - Messico 7
NL - Olanda 7
ZA - Sudafrica 7
MA - Marocco 4
PK - Pakistan 4
SA - Arabia Saudita 4
VE - Venezuela 4
CL - Cile 3
IL - Israele 3
LT - Lituania 3
UZ - Uzbekistan 3
BY - Bielorussia 2
CI - Costa d'Avorio 2
HR - Croazia 2
NG - Nigeria 2
PY - Paraguay 2
UY - Uruguay 2
AL - Albania 1
CO - Colombia 1
CR - Costa Rica 1
DK - Danimarca 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
EC - Ecuador 1
GR - Grecia 1
HN - Honduras 1
JM - Giamaica 1
KE - Kenya 1
KH - Cambogia 1
LV - Lettonia 1
MD - Moldavia 1
NI - Nicaragua 1
PH - Filippine 1
PR - Porto Rico 1
PS - Palestinian Territory 1
SI - Slovenia 1
SK - Slovacchia (Repubblica Slovacca) 1
SN - Senegal 1
TH - Thailandia 1
TN - Tunisia 1
TR - Turchia 1
Totale 5.417
Città #
Santa Clara 509
Warsaw 423
Ashburn 336
Singapore 218
Fairfield 209
Hong Kong 124
Dublin 119
Chandler 116
San Jose 102
Seattle 85
Woodbridge 77
Cambridge 68
Houston 68
Seoul 68
Wilmington 65
Beijing 53
Helsinki 49
Milan 48
Lawrence 43
Altamura 42
Ann Arbor 41
Buffalo 40
Council Bluffs 40
Rome 33
Moscow 31
Princeton 31
Ho Chi Minh City 28
Florence 27
Hanoi 27
Los Angeles 25
Boston 24
Lauterbourg 24
Munich 23
Mumbai 21
New York 21
Shanghai 20
Dallas 19
Dong Ket 18
Hefei 18
Boardman 17
Jakarta 16
Pisa 16
The Dalles 13
Medford 12
San Diego 12
Naples 11
Paris 11
Tokyo 11
Turku 11
Clifton 10
Vienna 10
Orem 9
Shenzhen 9
Toronto 9
Bologna 8
Da Nang 8
Redondo Beach 8
Bern 7
Brussels 7
North Charleston 7
Pune 7
Redwood City 7
Barcelona 6
Frankfurt am Main 6
Johannesburg 6
London 6
Norwalk 6
São Paulo 6
Atlanta 5
Barnet 5
Guangzhou 5
Melbourne 5
Mosier 5
Biên Hòa 4
Bremen 4
Curitiba 4
Falls Church 4
Hillsboro 4
Kent 4
Las Vegas 4
Miano 4
Perugia 4
Yubileyny 4
Amman 3
Amsterdam 3
Avon 3
Baghdad 3
Catania 3
Charlotte 3
Chennai 3
Genoa 3
Lucca 3
Mexico City 3
Mykolayiv 3
Nuremberg 3
Phoenix 3
Suzhou 3
Tashkent 3
Turin 3
Abidjan 2
Totale 3.720
Nome #
HERG1 positivity and Glut-1 negativity identifies high-risk TNM stage I and II colorectal cancer patients, regardless of adjuvant chemotherapy 339
Adjuvant chemotherapy in completely resected gastric cancer: A randomized phase III trial conducted by GOIRC 292
Gallbladder neuroendocrine neoplasm: a case report and critical evaluation of WHO classification 280
hERG1 and HIF-2α Behave as Biomarkers of Positive Response to Bevacizumab in Metastatic Colorectal Cancer Patients 258
hERG1 channels drive tumour malignancy and may serve as prognostic factor in pancreatic ductal adenocarcinoma 257
Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial 251
Osteonecrosis of the Jaw and Angiogenesis inhibitors: A Revival of a Rare but Serous Side Effect 231
KRAS and NRAS mutation detection in circulating DNA from patients with metastatic colorectal cancer using BEAMing assay: Concordance with standard biopsy and clinical evaluation 211
Evaluation of RAS mutational status through BEAMing assay to monitor disease progression of metastatic colorectal cancer: a case report 203
Bevacizumab plus XELOX as first-line treatment of metastatic colorectal cancer: The OBELIX study 199
Endocrine toxicity in cancer patients treated with nivolumab or pembrolizumab: results of a large multicentre study. 199
Circulating tumour cells in colorectal cancer 193
Physical exercise and eating habits in cancer survivors 189
Effects of a home based exercise rehabilitation program for cancer survivors 186
Oxaliplatin-Based Chemotherapy in Advanced Neuroendocrine Tumors: Clinical Outcomes and Preliminary Correlation with Biological Factors 185
Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues 185
A transcriptomic approach reveals selective ribosomal remodelling in the tumour versus the stromal compartment of metastatic colorectal cancer 173
Temperament and character traits associated with health-related quality of life in cancer patients 162
Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer. 162
Regorafenib also can cause osteonecrosis of the jaw 155
Quality of life, compliance, safety and effectiveness in fit older metastatic colorectal patients with cancer treated in first-line with chemotherapy plus cetuximab: A restrospective analysis from the ObservEr study 148
Prognostic role of hERG1 Potassium Channels in Neuroendocrine Tumours of the Ileum and Pancreas 144
Bevacizumab in non-small cell lung cancer 144
Phase II trial of single-agent oral vinorelbine in elderly (> or =70 years) patients with advanced non-small-cell lung cancer and poor performance status 141
A multi-center study on the surgical management of metastatic disease to adrenal glands 140
Phase II study of 5-FU plus 6-S-leucovorin (6S-LV) in advanced colorectal cancer 133
ITACA-S (Intergroup Trial of Adjuvant Chemotherapy in Adenocarcinoma of the Stomach) Trial: comparison of a sequential treatment with irinotecan (cpt-11) + 5-fluorouracil (5-FU)/folinic acid (LV) followed by docetaxel and cisplatin versus a 5-FU/LV regimen as postoperative treatment for radically resected gastric cancer 131
Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme 105
Everolimus as maintenance therapy in advanced neuroendocrine neoplasms: Results from the MAVERIC Phase II Trial (1499 WORDS MAIN TEXT) 89
Totale 5.485
Categoria #
all - tutte 16.050
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 16.050


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022224 8 17 21 8 5 15 5 15 19 13 31 67
2022/2023608 57 131 33 27 38 110 76 36 68 5 15 12
2023/2024225 3 19 28 12 10 50 15 47 2 16 12 11
2024/20251.542 45 151 79 285 437 206 22 66 75 46 64 66
2025/20261.653 175 197 88 87 181 75 250 88 119 136 59 198
2026/202769 69 0 0 0 0 0 0 0 0 0 0 0
Totale 5.485